Federated Hermes, Inc. Kronos Bio, Inc. Transaction History

Federated Hermes, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$1.23 - $2.25 $414 - $758	-337 Reduced 14.08%	2,056 $2,000
Q2 2023 Aug 14, 2023	SELL	$1.24 - $1.92 $206,006 - $318,977	-166,134 Reduced 98.58%	2,393 $4,000
Q1 2023 May 08, 2023	SELL	$1.34 - $2.62 $2,874 - $5,619	-2,145 Reduced 1.26%	168,527 $246,000
Q4 2022 Feb 13, 2023	BUY	$1.44 - $3.44 $5,420 - $12,948	3,764 Added 2.26%	170,672 $276,000
Q3 2022 Nov 14, 2022	SELL	$3.35 - $5.55 $397,165 - $657,991	-118,557 Reduced 41.53%	166,908 $559,000
Q2 2022 Aug 15, 2022	BUY	$3.12 - $7.52 $890,650 - $2.15 Million	285,465 New	285,465 $1.04 Million

19.8M

9.3K

100

Ticker KRON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,769,100
Market Cap $53.9M
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.